
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
SkinHealth Systems is a world-wide medical aesthetics company, focused on delivering clinically validated solutions to support superior skin health and provider success. Despite guidance and estimate changes, SkinHealth has strong financial fundamentals with a projected revenue of $280mn-$295mn and an EBITDA of $35mn-$45mn in 2026, along with strong gross margins and operational efficiency. However, there is a potential risk associated with provider and brand reputation for Hydrafacial, as well as regulatory risk due to the company's products being subject to medical-device and cosmetic regulations. Despite this, SkinHealth has reported strong 4Q sales, with the Hydrafacial treatment remaining #1 in the microdermabrasion category and plans to innovate and launch a new system in 2028. The consumables business has also shown growth and the company continues to invest in science-backed boosters. However, there is competition in the global skincare, beauty, and aesthetics markets which could affect the company's ability to sustain brand awareness and develop new products.
Bears say
SkinHealth Systems is facing multiple headwinds, including declining consumable revenue, ongoing SEC investigations, and ongoing litigation. Additionally, the company relies heavily on its Hydrafacial platform, making it vulnerable to any negative events or a decline in demand for the product. With the potential impact of macroeconomic factors on consumer spending and the complex and costly regulatory process for its products, there are significant risks to the company's future performance.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares